Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer.

Critical reviews in oncology/hematology·2023
Same author

Erratum to 'Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors': [ESMO Open Volume 7, Issue 2, April 2022, 100447].

ESMO open·2022
Same author

Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors.

ESMO open·2022
Same author

Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study.

ESMO open·2021
Same author

Study protocol: understanding the pathophysiologic mechanisms underlying delirium in older people undergoing hip fracture surgery.

BMC geriatrics·2021
Same author

A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study.

ESMO open·2021

Related Experiment Video

Updated: Jun 1, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Palliative radiotherapy for brain metastases.

V Tombolini, A Zurlo, A Montagna

    Oncology Reports
    |May 21, 2011
    PubMed
    Summary

    Hypofractionated radiotherapy for palliative brain metastases shows similar results to conventional doses. Short, cost-effective schedules are optimal for patients and institutions in most palliative scenarios.

    Area of Science:

    • Oncology
    • Radiotherapy
    • Palliative Care

    Background:

    • Conventional radiotherapy for brain metastases is often lengthy.
    • Hypofractionated schedules offer a shorter treatment course.
    • Previous studies suggest comparable efficacy between hypofractionated and conventional radiotherapy.

    Purpose of the Study:

    • To evaluate the efficacy of different hypofractionated radiotherapy schedules for palliative brain metastases.
    • To compare outcomes across various schedules and patient prognostic factors.
    • To determine the optimal hypofractionated schedule for palliative care.

    Main Methods:

    • Retrospective analysis of 56 consecutive patients with brain metastases treated between 1992-1993.
    • Irradiation using three different hypofractionated schedules (18-40 Gy).

    More Related Videos

    Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
    08:54

    Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

    Published on: May 8, 2018

    PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
    10:48

    PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

    Published on: December 28, 2017

    Related Experiment Videos

    Last Updated: Jun 1, 2026

    Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
    10:01

    Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

    Published on: August 2, 2022

    Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
    08:54

    Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

    Published on: May 8, 2018

    PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
    10:48

    PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

    Published on: December 28, 2017

  • Evaluation of overall survival, clinical response, and radiological response.

    • Main Results:

    • No significant differences in overall survival, clinical, or radiological response were observed between the different hypofractionated schedules.
    • Patients with shorter life expectancy were more likely to receive more hypofractionated radiotherapy.
    • Hypofractionated radiotherapy demonstrated comparable outcomes to conventional fractionation.

    Conclusions:

    • Hypofractionated radiotherapy is an effective palliative treatment for brain metastases.
    • Shorter, cost-effective hypofractionated schedules are recommended for palliative cases.
    • Treatment outcomes are similar across different hypofractionated schedules, offering flexibility in patient care.